COVID 19: Gastrointestinal and Hepatic Perspective

Balvir S Tomar1*, Deepak Nathiya2, Pankaj Kumar Singh3, Pratima Singh2, Supriya Suman2, Preeti Raj2, Sandeep Tripathi4 and Dushyant S Chauhan5

1Director - Institute of Gastroenterology, Hepatology and Transplant, Nims University Rajasthan and President - International Society of Gastroenterology, Hepatology, Transplant and Nutrition, India
2Department of Pharmacy Practice, Institute of Pharmacy, Nims University Rajasthan, Jaipur, India
3Department of Neurosurgery, National Institute of Medical Sciences and Research, Nims University Rajasthan, Jaipur, India
4Institute of Nutrition and Public Health, Nims University Rajasthan, Jaipur, India
5Institute of Advance Sciences, Nims University Rajasthan, Jaipur, India

*Corresponding Author: Balvir S Tomar, Professor, Director and Head, Institute of Gastroenterology and Hepatology, Nims University Rajasthan and President International Society of Gastroenterology, Hepatology, Transplant and Nutrition, India.

Received: April 24, 2020; Published: June 24, 2020

Abstract

Since December 2019, nCOV becomes threat to world and due to this WHO declared this as Pandemic. As of today andgt;2.6 Million confirmed cases along with andgt;182,000 deaths has been reported so far. Clinical symptoms include varieties of Pulmonary and extra pulmonary viz Pneumonia, Cough, diarrhoea. COVID-19 cause large number of changes in biochemical profile of individual who is suffering from it includes lymphocytopenia, high creatinine levels, high blood urea and significant effect on various inflammatory factors. RT-PCR method of testing stands as Gold standard for testing of COVID-19. Liver and Gastrointestinal features are much prevalent in COVID-19. Further number of drugs are under investigation /or their efficacies are yet to establish in COVID-19. Hypoxia plays important role in worsening of COVID-19 which must be controlled by monitoring Silent Hypoxia by Pulse Oximeter so that morbidities leading to mortalities can be minimized. Elderly patients must be given special care for prevention of COVID-19 among them. Further in this review we will be summarizing various effect on Hepatic and Gastrointestinal involvement in COVID-19, and preventive measures to be taken against spread of COVID-19 Pandemic.

Keywords: SARS-CoV2; Liver; Gastrointestinal; AST; ALT; Hypoxia

Background

In December 2019, a large number of pneumonia cases, caused by a newly recognized β-coronavirus, which is enveloped non-segmented positive-sense RNA virus, occurred in Wuhan, China. This coronavirus name was given by World Health Organization (WHO) in 2019 and name of disease as COVID 19 (Corona Virus Disease) in 2020. [1].

By April 2020, total of > 2.6 Million cases of COVID including > 182,000 deaths has been identified globally [2]. Studies suggested the doubling rate (R0) of SARS-CoV2 is around 2.2 [3] and ranges from 1.4 to 6.5 [4,5].

Coronaviruses (CoV) have four types of strains e.g. α/β/γ/δ-CoV, out of which α and β are prevalent for infection in humans, while γ and δ Corona virus strains are prevalent in birds [6]. Bat has been considered as inherited host of virus and transmitted by unspecified
hosts to humans. nCoV-2 could Use angiotensin-converting enzyme 2 (ACE2) as target for infection in humans, the same receptor which was used in SARS-CoV infection [7].

**Diagnostic criteria [8,9]**

<table>
<thead>
<tr>
<th>Clinical Specimens used for COVID-19 Testing</th>
<th>Serological Tests used for COVID-19 Testing</th>
<th>Molecular Tests used for COVID-19 Testing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nasal secretions (Snot)</td>
<td>Enzyme linked immunosorbent assay (ELISA)</td>
<td>Real-Time-PCR (RT-PCR) (Gold Standard)</td>
</tr>
<tr>
<td>Blood</td>
<td>Western blot (for detection of COVID-19 Proteins)</td>
<td>Northern blot hybridization targeting (for detection of COVID-19 genes)</td>
</tr>
<tr>
<td>Sputum (Saliva/Spit)</td>
<td>Direct immune fluorescent assay (IFA) (detection of Viral Antigen)</td>
<td></td>
</tr>
<tr>
<td>Bronchoalveolar Lavage (BAL)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 1: Diagnostics used for COVID-19.**

**Clinical symptoms**

A recent study of 1099 laboratory-confirmed cases, found that the common clinical manifestations included headache (13.6%), Sore throat (13.9%), Shortness of breath (18.6%), Sputum production (33.4%), fatigue (38.1%), cough (67.8%) and fever (88.7%). The geriatric people with unmet cardiovascular, pulmonary, hormonal disorders undergo Septic Shock, ARDS and can lead to death [10]. Hyperthermia and Tussis were presiding signs while URTI and GI signs were less or not available, were indicative of differences in viral tropism as compared with SARS-CoV [11], MERS-CoV [12] and influenza [13].

In Complete blood count test, majority of patients had low white blood cell counts, and lymphocytopenia [14]. But in the serious patients, the neutrophil, blood urea, and creatinine levels were higher there was continue increase in lymphocyte counts. Additionally, in laboratory tests it was found that inflammatory factors (tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-10 increases, indicating the immune status of patients. Further data suggested higher plasma level of Interleukin-2, Interleukin-7, Interleukin-10, granulocyte colony-stimulating factor (GCSF), monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein 1-α (MIP-1α) and TNF-α [12]. Furthermore, the CT Scan on chest was ground-glass opacity (56.4%) and bilateral patchy shadowing (51.8%) [10,15].

**COVID-19: Liver involvement**

Liver involvement has been reported in patients infected with SARS-CoV [16] and MERS-CoV [17]. Published case studies have suggested that Patient with SARS infection may develop different levels of liver abnormalities (summarized in table 2). In those studies, the incidence of liver injury ranged from 1.3% to 78%, mainly presenting with abnormal levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) accompanied by slightly elevated bilirubin levels [10,18-28].

<table>
<thead>
<tr>
<th>Name of Study</th>
<th>Number of Patients with COVID-19</th>
<th>Patients with abnormal biochemical liver profile</th>
<th>Patients with pre-existing liver co-morbidities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guan., et al [10]</td>
<td>1099</td>
<td>Abnormal ALT, 158/741 (21.3%):</td>
<td>23 (2.1%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 19.8% in non-severe COVID-19</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 28.1% in severe COVID-19</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal AST, 168/757 (22.2%):</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 18.2% in non-severe COVID-19</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 39.4% in severe COVID-19</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal total bilirubin 76/722 (10.5%):</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 9.9% in non-severe COVID-19</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 13.3% in severe COVID-19</td>
<td></td>
</tr>
<tr>
<td>Cai., et al. [18]</td>
<td>298</td>
<td>44 (14.8%):</td>
<td>8 (2.7%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 9.6% in non-severe COVID-19</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• 36.2% in severe COVID-19</td>
<td></td>
</tr>
</tbody>
</table>

**Citation:** Balvir S Tomar, et al. “COVID 19: Gastrointestinal and Hepatic Perspective”. EC Gastroenterology and Digestive System 7.7 (2020): 63-77.
Currently, the primary reasons for hepatic injury in patients with COVID-19 are still unclear. Liver damage might be directly caused by virus-induced cytopathic effects. SARS-CoV-2 binds to the angiotensin-converting enzyme 2 (ACE2) receptor to enter its target cells [29].

<table>
<thead>
<tr>
<th>Study</th>
<th>Patients</th>
<th>Abnormal ALT</th>
<th>Abnormal AST</th>
<th>Abnormal total bilirubin</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fan, et al. [19]</td>
<td>148</td>
<td>75 (50.7%)</td>
<td></td>
<td></td>
<td>6 (8%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal ALT (18.2%)</td>
<td>Abnormal AST (21.6%)</td>
<td>Abnormal total bilirubin (6.1%)</td>
<td></td>
</tr>
<tr>
<td>Wang et al [20]</td>
<td>138</td>
<td></td>
<td></td>
<td>Mild elevation of ALT and AST</td>
<td>4 (2.9%)</td>
</tr>
<tr>
<td>Chen et al [21]</td>
<td>99</td>
<td>43 (43%)</td>
<td></td>
<td></td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal ALT 28%</td>
<td>Abnormal AST 35%</td>
<td>Abnormal total bilirubin 18%</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal albumin 98%</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lu., et al. [22]</td>
<td>85</td>
<td>33 (38.8%)</td>
<td></td>
<td></td>
<td>6 (7%)</td>
</tr>
<tr>
<td>Shi., et al. [23]</td>
<td>81</td>
<td>43 (53%)</td>
<td></td>
<td></td>
<td>7 (9%)</td>
</tr>
<tr>
<td>Xu., et al. [24]</td>
<td>62</td>
<td>10 (16%)</td>
<td></td>
<td></td>
<td>7 (11%)</td>
</tr>
<tr>
<td>Yang., et al. [25]</td>
<td>52</td>
<td>15 (29%)</td>
<td></td>
<td></td>
<td>NA</td>
</tr>
<tr>
<td>Huang., et al. [26]</td>
<td>41</td>
<td>15 (31%)</td>
<td></td>
<td></td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Zhang., et al. [27]</td>
<td>82, deaths</td>
<td>64 (78%)</td>
<td></td>
<td></td>
<td>2 (2.4%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Abnormal ALT 30.6%</td>
<td>Abnormal AST 61.1%</td>
<td>Abnormal total bilirubin 30.6%</td>
<td></td>
</tr>
<tr>
<td>Huang., et al. [28]</td>
<td>36, non survivors</td>
<td></td>
<td>Abnormal ALT 13%</td>
<td>Abnormal AST 58%</td>
<td>Abnormal total bilirubin 12.9%</td>
</tr>
</tbody>
</table>

Table 2: Characteristics of liver biochemical profile in published COVID-19 case studies. Abbreviations: SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus 2; ALT: Alanine Transaminase; AST: Aspartate Aminotransferase.
Recently it's suggested that gamma-glutamyl transferase (GGT) was elevated in 54% of COVID-19 patients, whereas only 1.8% of patients (1/56) had elevated alkaline phosphatase level. Immune-mediated inflammation also may be the reason behind liver injury in severe ill patients [30,31].

Inflammatory cytokine over activity as seen in SARS-CoV and MERS-CoV [32,33], Continuously produces large amount of lymphocytes and macrophages which in turn releases large amount of Inflammatory Cytokines [34]. Lymphocytes plays crucial role during viral infection [35] and inhibit overactive natural immune response, thus lymphopenia during COVID-19 may increase IL-6, IL-10 and IFN-C levels leading to Pulmonary as well as other organ injury including Liver [36]. Drug induced liver injury must be taken care of as antiviral medications, Antipyretics, Antibiotics (Macrolides /Quinolones specially) or Steroids may increase chances of liver injury [37]. In USA, antiviral drug remdesivir reported to increase liver enzymes [38].

**COVID-19: Liver comorbidities**

The agenda need to be investigated thoroughly, however as of now it suggests to have around 2 - 11% of patients with COVID-19 and pre-existing liver diseases [30].

In a study there were hepatitis B infection present in patient with COVID-19 [10]. Individuals at high risk for severe COVID-19 are typically of older age and/or present with comorbid conditions such as diabetes, cardiovascular disease, and hypertension, a similar profile to those at increased risk for nonalcoholic fatty liver disease, making them more susceptible to liver injury [39]. Liver transplantation could have risk of viral [40].

**COVID-19: Gastrointestinal tract**

GIT involvement is well known because SARS-CoV-2 RNA was detected in a stool of COVID-19 patient [41,42]. Large number of studies have suggested that around 10.6% of patients with SARS and up to 30% of patients with MERS had diarrhea [43].

Similarly, in many studies of COVID-19, nausea, vomiting and diarrhoea are prevalent. In one study of COVID-19 large number of patient found with nausea or vomiting and diarrhoea [10].

In a recent study by Wei, et al. they noticed that COVID-19 patients with diarrhoea are more prone towards headache, myalgia or fatigue, cough, sputum production, nausea, and vomiting in comparison with patient patients without diarrhoea [45].

A comparison of gastrointestinal symptoms in COVID-19, SARS, MERS are summarized in table 3 [44].

<table>
<thead>
<tr>
<th>Covid-19</th>
<th>Subject number</th>
<th>Diarrhoea</th>
<th>Nausea</th>
<th>Vomiting</th>
<th>Abdominal pain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Guan W., et al. [49]</td>
<td>1099</td>
<td>42 (3.8%)</td>
<td>55 (5.0%)</td>
<td>55 (5.0%)</td>
<td>NA</td>
</tr>
<tr>
<td>Chen N., et al. [50]</td>
<td>99</td>
<td>2 (2.0%)</td>
<td>1 (1%)</td>
<td>1 (1%)</td>
<td>NA</td>
</tr>
<tr>
<td>Huang C., et al. [51]</td>
<td>38</td>
<td>1 (2.6%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Liu K., et al. [52]</td>
<td>137</td>
<td>11 (8%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Lu X., et al. [53]</td>
<td>171</td>
<td>15 (8.8%)</td>
<td>NA</td>
<td>11 (6.4%)</td>
<td>NA</td>
</tr>
<tr>
<td>Shi H., et al. [54]</td>
<td>81</td>
<td>3 (3.7%)</td>
<td>NA</td>
<td>4 (4.9%)</td>
<td>NA</td>
</tr>
<tr>
<td>Wang D., et al. [55]</td>
<td>138</td>
<td>14 (10.1%)</td>
<td>14 (10.1%)</td>
<td>5 (3.6%)</td>
<td>3 (2.2%)</td>
</tr>
<tr>
<td>Xu XW, et al. [56]</td>
<td>62</td>
<td>3 (4.8%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Yang X., et al. [57]</td>
<td>52</td>
<td>NA</td>
<td>NA</td>
<td>2 (3.8%)</td>
<td>NA</td>
</tr>
</tbody>
</table>

**Citation:** Balvir S Tomar, et al. “COVID 19: Gastrointestinal and Hepatic Perspective”. EC Gastroenterology and Digestive System 7.7 (2020): 63-77.
There are many hypotheses regarding why COVID-19 appears to cause digestive symptoms, but the exact molecular mechanism needs to be further investigated. First, interaction between SARS-CoV-2 and ACE2 might result in diarrhea [46]. Second, SARS-CoV-2 cause damage to digestive system via inflammatory response mediated pathway [44]. Another possible factor causing diarrhoea in COVID-19 patients might be antibiotic associated [45]. It may be due to changes in the composition and function of GI flora mutually affect the respiratory tract through immune regulation, the so-called "gut-lung axis" [47]. Autopsy studies are needed to understand the digestive system involvement of COVID-19 [48].

**COVID-19: Digestive comorbidities**

In general, presence of co-morbidities is associated with poorer outcomes in patients with COVID-19 [77]. Cancer comorbid Patients are more prone to infection. Further patient with GI Cancer are more susceptible toward SARS-CoV-2 Infection [48]. In an analysis, around 18 (1%) of 1590 COVID-19 cases were having a history of cancer [78].

**COVID-19 and endoscopy**

In whole world health-care workers are at highest risk from COVID-19. However, they are not directly involved in treatment of COVID 19. Workforce working in endoscopy units are still at increased risk from inhalation of air- borne droplets, conjunctival contact, and touch contamination [79].

**Table 3:** Presentation of gastrointestinal symptoms in coronavirus infection: a comparison of Covid-19, SARS, MERS in major clinical cohorts. Case reports, series or cohorts with less than twenty subjects are not included.
All endoscopy department along with infection control department must develop standard operating measures to be taken for CO-
VID-19 prevention and control with the help of prior experience of SARS and current understanding of epidemiological characteristics of
COVID-19. The following steps should be implemented in endoscopy units:

- **Reduction of non-essential exposure to SARS-CoV-2:** It is recommended to limit endoscopy during the current COVID-19 outbreak to emergency procedures only, e.g. acute gastrointestinal bleeding, acute cholangitis etc [80].

- **Risk assessment and stratification of patients prior to any endoscopic procedure:** Risk assessment and screening of patients to prevent transmission of COVID-19, should be based on case definitions established by WHO and local health authorities [81]. E.g. history of fever, respiratory symptoms, history of contact with a suspected or confirmed case of COVID-19 etc [82].

- **Staff protection:** The minimal composition of personal protective equipment (PPE) for personnel in endoscopy units should include gloves, hairnet, protective eyewear (goggles or face shield), waterproof gowns, and respiratory protective equipment, modified on the basis of risk stratification [82]. The surgical facial mask is effective in blocking splashes and large-particle droplets, whereas, filtering face piece (FFP) respirator class 2 or 3 (FFP2/FFP3) achieves efficient filtration of airborne particles (up to 0.3 mm) [83].

- **Reprocessing of endoscopes and endoscopic accessories:** Enveloped viruses such as SARS-CoV-2 can be inactivated by disinfectants having virucidal activity [84]. Whereas high-level disinfection is recommended for endoscopes, and other semi-critical instruments, sterilization is recommended for “critical” instruments, including biopsy forceps, polypectomy snares and papillotomes. Disposable accessories may be used [85].

- **Decontamination of endoscopy rooms:** Sanitization with 1% Sodium hypochlorite is recommended for floor cleaning every day [84].

**Figure 1:** Suggested workflow in GI endoscopy units during SARS-CoV-2 outbreak [80-86].
Treatment of COVID-19

Therapies which are being used against COVID-19 have less specific antiviral effect and just provide only a symptomatic relief at some level along with pulmonary support and are according to guidelines issued by National Health Commission of the People’s Republic of China [87]. Almost all patient with hypoxemia receives oxygen therapy and WHO recommended ECMO [88]. Treatment with plasma and IgG are also useful and being delivered according to condition of patient and found useful [89].

Remdesivir

It have wide spectrum antiviral activity against large number of RNA viruses. Data suggested that it could interfere with the NSP (Non-structural protein)12 polymerase [90]. Remdesivir found useful in treatment of many cases in USA against COVID-19 successfully [91].

Chloroquine

Chloroquine is widely used antimalarial drug [92]. Its antiviral mechanism is not much understood but it possibly inhibits pH-dependent steps of the replication of several viruses (Autophagy Inhibitor) [93], Several studies have found that chloroquine interfered with the glycosylation of cellular receptors of SARS-CoV [94]. Moreover, chloroquine suppresses the production of TNF-α and IL-6 [95].

Lopinavir and ritonavir

These drugs are protease inhibitor and used in HIV Infection and found useful in treatment of MERS-CoV [96] and SARSCoV [97] patients. Viral load of COVID-19 significantly decreased in South Korea after treatment by these drugs [98].

Other antiviral drugs are in table 4 below.

<table>
<thead>
<tr>
<th>Status</th>
<th>Drugs</th>
<th>Action mode</th>
<th>Anti-infective mechanism</th>
<th>Target diseases</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved</td>
<td>Lopinavir/Ritonavir</td>
<td>Protease inhibitors</td>
<td>Inhibiting HIV-1 protease for protein cleavage, resulting in non-infectious, immature viral particles</td>
<td>HIV/AIDS, SARS, MERS</td>
<td>[96-97,100]</td>
</tr>
<tr>
<td>Approved</td>
<td>Ribavirin</td>
<td>Synthetic guanosine nucleoside</td>
<td>Interfering with the synthesis of viral mRNA (a broad-spectrum activity against several RNA and DNA viruses)</td>
<td>HCV, SARS, MERS</td>
<td>[101-103]</td>
</tr>
<tr>
<td>Approved</td>
<td>Oseltamivir</td>
<td>Neuraminidase inhibitor</td>
<td>Inhibiting the activity of the viral neuraminidase enzyme, preventing budding from the host cell, viral replication, and infectivity</td>
<td>Influenza viruses A</td>
<td>[104,105]</td>
</tr>
<tr>
<td>Approved, Investigational</td>
<td>Ganciclovir</td>
<td>Nucleoside analog</td>
<td>Potent inhibitor of the Herpesvirus family including cytomegalovirus</td>
<td>AIDS-associated cytomegalovirus infections</td>
<td>[106]</td>
</tr>
<tr>
<td>Approved, Investigational, Vet approved</td>
<td>Nitazoxanide</td>
<td>Antiprotozoal agent</td>
<td>Modulating the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, viruses</td>
<td>A wide range of viruses</td>
<td>[107-109]</td>
</tr>
</tbody>
</table>

Citation: Balvir S Tomar, et al. "COVID 19: Gastrointestinal and Hepatic Perspective". EC Gastroenterology and Digestive System 7.7 (2020): 63-77.
Approved, Investigational, Vet approved

**Approved, Investigational, Vet approved**

<table>
<thead>
<tr>
<th>Mohammad, et al.</th>
<th>Chloroquine / Hydroxychloroquine</th>
<th>9-aminoquinolin</th>
<th>Increasing endosomal pH, immunomodulating, autophagy inhibitors</th>
<th>Malaria, autoimmune disease</th>
<th>[93-95]</th>
</tr>
</thead>
</table>

**Experimental**

<table>
<thead>
<tr>
<th>Remdesivir (GS-5734)</th>
<th>Nucleotide analogue prodrug</th>
<th>Interfering with virus post-entry</th>
<th>Ebola, SARS, MERS (A wide array of RNA viruses)</th>
<th>[90,110,111]</th>
</tr>
</thead>
</table>

**Investigational**

<table>
<thead>
<tr>
<th>Nafamostat</th>
<th>Synthetic serine protease inhibitor</th>
<th>Prevents membrane fusion by reducing the release of cathepsin B; anticoagulant activities</th>
<th>Influenza, MERS, Ebola</th>
<th>[112,113]</th>
</tr>
</thead>
</table>

**Investigational**

<table>
<thead>
<tr>
<th>Favipiravir (T-705)</th>
<th>Nucleoside analog: Viral RNA polymerase inhibitor</th>
<th>Acting on viral genetic copying to prevent its reproduction, without affecting host cellular RNA or DNA synthesis</th>
<th>Ebola, influenza A(H1N1)</th>
<th>[114-116]</th>
</tr>
</thead>
</table>

**Table 4: Common and potent antiviral drugs.**


Golden Opinion – "Silent hypoxia": It’s Significant role in COVID-19 morbidity leading to Mortality and Use of Pulse Oximeter may reduce utilization of Ventilators for COVID-19 Patients by early detection of Hypoxia [118]

Pneumonia is an infection of the lungs in which the air sacs fill with fluid or pus. Normally, patients develop chest congestion and breathing problems. But when Covid pneumonia first attacks, patients don’t feel shortness of breath, even when oxygen levels low. And by the time they feel its, they have severe low oxygen levels which lead to pneumonia. Normal oxygen saturation level is 94 percent to 100 percent; in Covid pneumonia patients it goes as low as 50 percent.

In spite of significant hypoxia, Patient looks like asymptomatic: Why?

“The coronavirus attacks lung cells that make surfactant. This helps the air sacs in the lungs stay open between breaths and is important for normal lung functioning. As the COVID 19 pneumonia progresses, it causes the air sacs to collapse, and oxygen levels reduces. Yet the lungs initially remain “fine,” not become stiff or heavy with fluid. This means patients can still expel carbon dioxide - and without a buildup of carbon dioxide, patients do not feel short of breath.” Further in SARS-2 Corona. In the lungs, blood vessel constriction phenomenon also seen in pneumonia caused by COVID-19: Some patients have extremely low blood-oxygen levels and yet are fine for breath. It’s possible that at some stages of disease, the virus alters the balance of hormones that helps in regulation of blood pressure and constricts blood vessels going to the lungs. So, oxygen uptake is impeded by constricted blood vessels, rather than by clogged alveoli.

Patients compensate for the reduced oxygen supply in their blood by breathing faster and deeper, and they do without realizing it. This silent hypoxia and the patient’s physiological response to it, causes even more inflammation and more air sacs to collapse and the pneumonia worsens. In effect, patients are injuring their own lungs by breathing harder and harder by this Fluid builds up and the lungs become stiff, carbon dioxide rises, and patients develop acute respiratory failure.

**Citation:** Balvir S Tomar, et al. "COVID 19: Gastrointestinal and Hepatic Perspective." **EC Gastroenterology and Digestive System** 7.7 (2020): 63-77.
"We can identify these positive patient bit early and can treat them in more better way. It just requires detection of silent hypoxia early through a common medical device know as "Pulse oximeter".

Pulse oximetry is as simple as thermometer in usage. These small devices turn on with one button and are placed on a fingertip. All COVID-19 positive patients should have pulse oximetry monitoring at least for two weeks, it's the time in which pneumonia typically develops. All persons with cough, fatigue and fevers should also have pulse oximeter monitoring.

Conclusion

Scientists all over the world are continuously working to find vaccine and effective therapy against COVID-19. We had summarized COVID-19 review as:

1. Elderly and people with certain comorbidities are found to be most prone towards infection of COVID-19, which requires continuous attention and care.

2. Pneumonia cause by COVID-19 is strong in infectivity but less in virulence compared to SARS and MERS, in terms of mortality and morbidity.

3. So far till date, not specific treatment is available and antiviral drugs, such as remdesivir, or lopinavir/ritonavir, are being used which need solid data from more clinical trials to strengthen their efficacy towards COVID-19.

4. Large number multicentric studies required to be conducted to explore the transmission and pathogenicity mechanism of coronavirus, Molecular mechanism of viral replication for future development of treatment and vaccines.

5. Due to large number of patients, doctors are facing and bearing enormous pressure and severe challenge, including a high risk of infection and inadequate protection, as well as overwork, frustration and exhaustion [117].

6. Maintaining early hypoxia by pulse oximeter may reduce the requirement of ventilator and thus may reduce the morbidity and ultimately mortality [118].

Bibliography


COVID 19: Gastrointestinal and Hepatic Perspective


Citation: Balvir S Tomar, et al. "COVID 19: Gastrointestinal and Hepatic Perspective". EC Gastroenterology and Digestive System 7.7 (2020): 63-77.
COVID-19: Gastrointestinal and Hepatic Perspective


COVID 19: Gastrointestinal and Hepatic Perspective


Citation: Balvir S Tomar, et al. "COVID 19: Gastrointestinal and Hepatic Perspective". EC Gastroenterology and Digestive System 7.7 (2020): 63-77.
COVID 19: Gastrointestinal and Hepatic Perspective


88. WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected (2020).


Citation: Balvir S Tomar, et al. "COVID 19: Gastrointestinal and Hepatic Perspective". EC Gastroenterology and Digestive System 7.7 (2020): 63-77.
COVID 19: Gastrointestinal and Hepatic Perspective


Volume 7 Issue 7 July 2020
© All rights reserved by Balvir S Tomar, et al.